ME01663B - Derivati N-(1H-indolil)-1H-indol-2-karboksamida, njihova priprema i njihova primena u terapiji - Google Patents
Derivati N-(1H-indolil)-1H-indol-2-karboksamida, njihova priprema i njihova primena u terapijiInfo
- Publication number
- ME01663B ME01663B MEP-2009-366A MEP36609A ME01663B ME 01663 B ME01663 B ME 01663B ME P36609 A MEP36609 A ME P36609A ME 01663 B ME01663 B ME 01663B
- Authority
- ME
- Montenegro
- Prior art keywords
- indole
- carboxamide
- methyl
- fluoro
- benzyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 3
- -1 7-indolyl Chemical group 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- XEMBTFIOTUQYJX-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C1=C(C)C(C)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 XEMBTFIOTUQYJX-UHFFFAOYSA-N 0.000 claims 1
- RESCOSDATXKCKQ-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-n-(1,2,3-trimethylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC(C)=CC(C)=C1 RESCOSDATXKCKQ-UHFFFAOYSA-N 0.000 claims 1
- LHAXLZHTJMEWSN-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-n-(1-methylindol-4-yl)indole-2-carboxamide Chemical compound CC1=CC(C)=CC(N2C3=CC=CC=C3C=C2C(=O)NC=2C=3C=CN(C)C=3C=CC=2)=C1 LHAXLZHTJMEWSN-UHFFFAOYSA-N 0.000 claims 1
- WRSHALSTTLXOBK-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound CC1=CC(C)=CC(N2C3=CC=CC=C3C=C2C(=O)NC=2C=C3C=CN(C)C3=CC=2)=C1 WRSHALSTTLXOBK-UHFFFAOYSA-N 0.000 claims 1
- QEHWFOLQFKREGZ-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-n-(1-methylindol-6-yl)indole-2-carboxamide Chemical compound CC1=CC(C)=CC(N2C3=CC=CC=C3C=C2C(=O)NC=2C=C3N(C)C=CC3=CC=2)=C1 QEHWFOLQFKREGZ-UHFFFAOYSA-N 0.000 claims 1
- ANGVFZCMZZBOTL-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-n-(1-methylindol-7-yl)indole-2-carboxamide Chemical compound CC1=CC(C)=CC(N2C3=CC=CC=C3C=C2C(=O)NC=2C=3N(C)C=CC=3C=CC=2)=C1 ANGVFZCMZZBOTL-UHFFFAOYSA-N 0.000 claims 1
- DZSQBANJDKLFEQ-UHFFFAOYSA-N 1-(4-butan-2-ylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 DZSQBANJDKLFEQ-UHFFFAOYSA-N 0.000 claims 1
- ZBZXXQHUNVUFKB-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC=C(Cl)C=C1 ZBZXXQHUNVUFKB-UHFFFAOYSA-N 0.000 claims 1
- BYVCNTTXPFCIAJ-UHFFFAOYSA-N 1-(4-cyclohexylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C(C=C1)=CC=C1C1CCCCC1 BYVCNTTXPFCIAJ-UHFFFAOYSA-N 0.000 claims 1
- BYOPYZVDBRXFDV-UHFFFAOYSA-N 1-(4-cyclopentylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C(C=C1)=CC=C1C1CCCC1 BYOPYZVDBRXFDV-UHFFFAOYSA-N 0.000 claims 1
- LLZIPBFFRVHYLK-UHFFFAOYSA-N 1-(4-ethoxyphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 LLZIPBFFRVHYLK-UHFFFAOYSA-N 0.000 claims 1
- SIPMYMRFSJXORU-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC=C(C(C)(C)C)C=C1 SIPMYMRFSJXORU-UHFFFAOYSA-N 0.000 claims 1
- XXQBFTAXUUILII-UHFFFAOYSA-N 1-[(3,5-difluorophenyl)methyl]-5-fluoro-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC(F)=CC(F)=C1 XXQBFTAXUUILII-UHFFFAOYSA-N 0.000 claims 1
- SPKYIDYOTSDFBP-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-4,6-dimethoxy-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C12=CC(OC)=CC(OC)=C2C=C(C(=O)NC=2C=C3C=CN(C)C3=CC=2)N1CC1=CC=CC(F)=C1 SPKYIDYOTSDFBP-UHFFFAOYSA-N 0.000 claims 1
- LLVXFBIURCXOKK-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-4-methoxy-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC=2C(OC)=CC=CC=2N1CC1=CC=CC(F)=C1 LLVXFBIURCXOKK-UHFFFAOYSA-N 0.000 claims 1
- RSFMTRKPZCEOIO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5,6-dimethoxy-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C1=2C=C(OC)C(OC)=CC=2C=C(C(=O)NC=2C=C3C=CN(C)C3=CC=2)N1CC1=CC=CC(F)=C1 RSFMTRKPZCEOIO-UHFFFAOYSA-N 0.000 claims 1
- VBXOAIPLLKAQJZ-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-methoxy-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(OC)=CC=C2N1CC1=CC=CC(F)=C1 VBXOAIPLLKAQJZ-UHFFFAOYSA-N 0.000 claims 1
- XISVBLDVMHXXQP-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-methyl-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C)=CC=C2N1CC1=CC=CC(F)=C1 XISVBLDVMHXXQP-UHFFFAOYSA-N 0.000 claims 1
- QCNWLWAHOOBMQH-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-6-methoxy-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)NC=2C=C3C=CN(C)C3=CC=2)N1CC1=CC=CC(F)=C1 QCNWLWAHOOBMQH-UHFFFAOYSA-N 0.000 claims 1
- PPGHAVJKVOFXCQ-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)-5-(trifluoromethyl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C(F)(F)F)=CC=C2N1CC1=CC=CC(F)=C1 PPGHAVJKVOFXCQ-UHFFFAOYSA-N 0.000 claims 1
- LZKFXCXPVSBSSF-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)-5-methylsulfonylindole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(S(C)(=O)=O)=CC=C2N1CC1=CC=CC(F)=C1 LZKFXCXPVSBSSF-UHFFFAOYSA-N 0.000 claims 1
- JLVUYOYEABKNBI-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)-5-nitroindole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC([N+]([O-])=O)=CC=C2N1CC1=CC=CC(F)=C1 JLVUYOYEABKNBI-UHFFFAOYSA-N 0.000 claims 1
- AOXVTBNQGHMMBY-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-5-fluoro-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=C(Br)C=C1 AOXVTBNQGHMMBY-UHFFFAOYSA-N 0.000 claims 1
- YCUCGGGBLIBGGT-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methyl]-5-fluoro-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=C(C(C)(C)C)C=C1 YCUCGGGBLIBGGT-UHFFFAOYSA-N 0.000 claims 1
- ZBHKIDRBRBSQTR-UHFFFAOYSA-N 1-[2-(4-tert-butylphenyl)ethyl]-5-fluoro-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=C(C(C)(C)C)C=C1 ZBHKIDRBRBSQTR-UHFFFAOYSA-N 0.000 claims 1
- ZZZLSVPUMMCMND-UHFFFAOYSA-N 1-benzyl-5-fluoro-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC=C1 ZZZLSVPUMMCMND-UHFFFAOYSA-N 0.000 claims 1
- NBASXJFABOKQHN-UHFFFAOYSA-N 1-benzyl-n-(1-methylindol-5-yl)-5-(trifluoromethyl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C(F)(F)F)=CC=C2N1CC1=CC=CC=C1 NBASXJFABOKQHN-UHFFFAOYSA-N 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- MRAROPGXEFBQNF-UHFFFAOYSA-N 4-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=C(F)C=CC=C2N1CC1=CC=CC(F)=C1 MRAROPGXEFBQNF-UHFFFAOYSA-N 0.000 claims 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 1
- GDOCKLVBTDWLOW-UHFFFAOYSA-N 4-methoxy-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC=2C(OC)=CC=CC=2N1CC1=CC=CC(C(F)(F)F)=C1 GDOCKLVBTDWLOW-UHFFFAOYSA-N 0.000 claims 1
- PYYQIDRCCNDUHF-UHFFFAOYSA-N 5-amino-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(N)=CC=C2N1CC1=CC=CC(F)=C1 PYYQIDRCCNDUHF-UHFFFAOYSA-N 0.000 claims 1
- SVXXMNBOAZRACG-UHFFFAOYSA-N 5-fluoro-1-[(2-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC=C1F SVXXMNBOAZRACG-UHFFFAOYSA-N 0.000 claims 1
- TWRBIVIOCQTOTC-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1,2,3-trimethylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 TWRBIVIOCQTOTC-UHFFFAOYSA-N 0.000 claims 1
- UCHPGIHMLSBKBH-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-4-yl)indole-2-carboxamide Chemical compound C1=CC=C2N(C)C=CC2=C1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 UCHPGIHMLSBKBH-UHFFFAOYSA-N 0.000 claims 1
- WZJFMHIURRCYNA-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 WZJFMHIURRCYNA-UHFFFAOYSA-N 0.000 claims 1
- MNPZAQDKUCYCFY-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-6-yl)indole-2-carboxamide Chemical compound C1=C2N(C)C=CC2=CC=C1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 MNPZAQDKUCYCFY-UHFFFAOYSA-N 0.000 claims 1
- KVBINSOTLAPAOD-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-7-yl)indole-2-carboxamide Chemical compound C=12N(C)C=CC2=CC=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 KVBINSOTLAPAOD-UHFFFAOYSA-N 0.000 claims 1
- OCSHTBUKRNOLMC-UHFFFAOYSA-N 5-fluoro-1-[(3-fluorophenyl)methyl]-n-(1h-indol-5-yl)indole-2-carboxamide Chemical compound FC1=CC=CC(CN2C3=CC=C(F)C=C3C=C2C(=O)NC=2C=C3C=CNC3=CC=2)=C1 OCSHTBUKRNOLMC-UHFFFAOYSA-N 0.000 claims 1
- KIFDJMDIKHFCBH-UHFFFAOYSA-N 5-fluoro-1-[(3-methoxyphenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound COC1=CC=CC(CN2C3=CC=C(F)C=C3C=C2C(=O)NC=2C=C3C=CN(C)C3=CC=2)=C1 KIFDJMDIKHFCBH-UHFFFAOYSA-N 0.000 claims 1
- VTLUIZCIFCASEJ-UHFFFAOYSA-N 5-fluoro-1-[2-(2-fluorophenyl)ethyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=CC=C1F VTLUIZCIFCASEJ-UHFFFAOYSA-N 0.000 claims 1
- YSODFKFTSIZCFB-UHFFFAOYSA-N 5-fluoro-1-[2-(3-fluorophenyl)ethyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=CC(F)=C1 YSODFKFTSIZCFB-UHFFFAOYSA-N 0.000 claims 1
- ZEHLINUXLYERIS-UHFFFAOYSA-N 5-fluoro-1-[2-(4-fluorophenyl)ethyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=C(F)C=C1 ZEHLINUXLYERIS-UHFFFAOYSA-N 0.000 claims 1
- BNQVEJJPTBVVEW-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-(2-phenylethyl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=CC=C1 BNQVEJJPTBVVEW-UHFFFAOYSA-N 0.000 claims 1
- LPKFOONNCXASRS-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-(3-phenylpropyl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCCC1=CC=CC=C1 LPKFOONNCXASRS-UHFFFAOYSA-N 0.000 claims 1
- BXVARQLOXVWVLY-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[(3-methylphenyl)methyl]indole-2-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC=C(F)C=C3C=C2C(=O)NC=2C=C3C=CN(C)C3=CC=2)=C1 BXVARQLOXVWVLY-UHFFFAOYSA-N 0.000 claims 1
- CVCARFFCZUUJGK-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[2-[3-(trifluoromethyl)phenyl]ethyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CCC1=CC=CC(C(F)(F)F)=C1 CVCARFFCZUUJGK-UHFFFAOYSA-N 0.000 claims 1
- ATQGGUOQGHUAHI-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[3-(trifluoromethyl)phenyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1C1=CC=CC(C(F)(F)F)=C1 ATQGGUOQGHUAHI-UHFFFAOYSA-N 0.000 claims 1
- HGJXRLSKTRNSFT-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethoxy)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(OC(F)(F)F)=C1 HGJXRLSKTRNSFT-UHFFFAOYSA-N 0.000 claims 1
- BIEDVVUIZZHCAH-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(C(F)(F)F)=C1 BIEDVVUIZZHCAH-UHFFFAOYSA-N 0.000 claims 1
- NVRRBGMCNDNIFE-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[[4-(trifluoromethoxy)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=C(OC(F)(F)F)C=C1 NVRRBGMCNDNIFE-UHFFFAOYSA-N 0.000 claims 1
- NPJGTSHNJCPYFY-UHFFFAOYSA-N 5-fluoro-n-(1-methylindol-5-yl)-1-[[4-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=C(C(F)(F)F)C=C1 NPJGTSHNJCPYFY-UHFFFAOYSA-N 0.000 claims 1
- XTJFHWOUXRBLLJ-UHFFFAOYSA-N 5-methoxy-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(OC)=CC=C2N1CC1=CC=CC(C(F)(F)F)=C1 XTJFHWOUXRBLLJ-UHFFFAOYSA-N 0.000 claims 1
- DIKIZFWFLNJYNE-UHFFFAOYSA-N 5-methoxy-n-(1-methylindol-5-yl)-1-phenylindole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(OC)=CC=C2N1C1=CC=CC=C1 DIKIZFWFLNJYNE-UHFFFAOYSA-N 0.000 claims 1
- RMNSADJYDNQOTP-UHFFFAOYSA-N 5-methyl-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C)=CC=C2N1CC1=CC=CC(C(F)(F)F)=C1 RMNSADJYDNQOTP-UHFFFAOYSA-N 0.000 claims 1
- QKXQEIZWQCDNMV-UHFFFAOYSA-N 5-tert-butyl-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C(C)(C)C)=CC=C2N1CC1=CC=CC(F)=C1 QKXQEIZWQCDNMV-UHFFFAOYSA-N 0.000 claims 1
- ZPLXKBHKVPJAJN-UHFFFAOYSA-N 6-fluoro-1-[(3-fluorophenyl)methyl]-n-(1-methylindol-5-yl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=C(F)C=C2N1CC1=CC=CC(F)=C1 ZPLXKBHKVPJAJN-UHFFFAOYSA-N 0.000 claims 1
- SLOOMVZGLLTPLC-UHFFFAOYSA-N 6-methoxy-n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)NC=2C=C3C=CN(C)C3=CC=2)N1CC1=CC=CC(C(F)(F)F)=C1 SLOOMVZGLLTPLC-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000000187 Abnormal Reflex Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000001375 Facial Neuralgia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000007893 Salpingitis Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000003728 Vulvodynia Diseases 0.000 claims 1
- 206010069055 Vulvovaginal pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 208000012790 cranial neuralgia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 231100000013 eye irritation Toxicity 0.000 claims 1
- 208000037907 haemorrhagic injury Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000035859 hyperreflexia Effects 0.000 claims 1
- 206010020745 hyperreflexia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 231100000017 mucous membrane irritation Toxicity 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- ONXBIKKHXGBYAS-UHFFFAOYSA-N n-(1,2-dimethylindol-5-yl)-5-fluoro-1-[(3-fluorophenyl)methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C(C)=CC2=CC=1NC(=O)C1=CC2=CC(F)=CC=C2N1CC1=CC=CC(F)=C1 ONXBIKKHXGBYAS-UHFFFAOYSA-N 0.000 claims 1
- FXVWVQCFUHOPMJ-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-(3-methylphenyl)indole-2-carboxamide Chemical compound CC1=CC=CC(N2C3=CC=CC=C3C=C2C(=O)NC=2C=C3C=CN(C)C3=CC=2)=C1 FXVWVQCFUHOPMJ-UHFFFAOYSA-N 0.000 claims 1
- AZVJTAHAPDEPPQ-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-(4-methylsulfanylphenyl)indole-2-carboxamide Chemical compound C1=CC(SC)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 AZVJTAHAPDEPPQ-UHFFFAOYSA-N 0.000 claims 1
- DHEANDQOUOMAPL-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-(4-pentylphenyl)indole-2-carboxamide Chemical compound C1=CC(CCCCC)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 DHEANDQOUOMAPL-UHFFFAOYSA-N 0.000 claims 1
- GUGRYPMHQFYIEZ-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-(4-phenylphenyl)indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C(C=C1)=CC=C1C1=CC=CC=C1 GUGRYPMHQFYIEZ-UHFFFAOYSA-N 0.000 claims 1
- QMGSFHPXAWIIKO-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-(4-propylphenyl)indole-2-carboxamide Chemical compound C1=CC(CCC)=CC=C1N1C2=CC=CC=C2C=C1C(=O)NC1=CC=C(N(C)C=C2)C2=C1 QMGSFHPXAWIIKO-UHFFFAOYSA-N 0.000 claims 1
- USMBQPADXNCRMG-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-[3-(trifluoromethyl)phenyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC=CC(C(F)(F)F)=C1 USMBQPADXNCRMG-UHFFFAOYSA-N 0.000 claims 1
- GIEDNAUCEWYYDK-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-[4-(trifluoromethyl)phenyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC=C(C(F)(F)F)C=C1 GIEDNAUCEWYYDK-UHFFFAOYSA-N 0.000 claims 1
- NLGVAOXKERHLNB-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1CC1=CC=CC(C(F)(F)F)=C1 NLGVAOXKERHLNB-UHFFFAOYSA-N 0.000 claims 1
- CJSWBQXJAYMRRY-UHFFFAOYSA-N n-(1-methylindol-5-yl)-1-phenylindole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC=CC=C2N1C1=CC=CC=C1 CJSWBQXJAYMRRY-UHFFFAOYSA-N 0.000 claims 1
- GPVFRLVITMDGKM-UHFFFAOYSA-N n-(1-methylindol-5-yl)-5-(trifluoromethyl)-1-[[3-(trifluoromethyl)phenyl]methyl]indole-2-carboxamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)C1=CC2=CC(C(F)(F)F)=CC=C2N1CC1=CC=CC(C(F)(F)F)=C1 GPVFRLVITMDGKM-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0408652A FR2874015B1 (fr) | 2004-08-05 | 2004-08-05 | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| PCT/FR2005/002014 WO2006024776A1 (fr) | 2004-08-05 | 2005-08-02 | Derives de n-(1 h-indolyl)-i h-ind0le-2-carb0xamides, leur preparation et leur application en therapeutique |
| EP05793766A EP1776340B1 (fr) | 2004-08-05 | 2005-08-02 | Derives de n-(1 h-indolyl)-i h-ind0le-2-carb0xamides, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01663B true ME01663B (me) | 2010-08-31 |
Family
ID=34950701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-366A ME01663B (me) | 2004-08-05 | 2005-08-02 | Derivati N-(1H-indolil)-1H-indol-2-karboksamida, njihova priprema i njihova primena u terapiji |
Country Status (37)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
| FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| BRPI0812594A2 (pt) * | 2007-08-10 | 2015-06-23 | Lundbeck & Co As H | Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo. |
| JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926555B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
| FR3007850B1 (fr) | 2013-06-28 | 2015-07-17 | Probayes | Systeme de prediction de temperature |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| DK0885215T3 (da) * | 1996-02-13 | 2006-08-14 | Abbott Lab | Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister |
| TR200101233T2 (tr) * | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| AU2002364549B2 (en) * | 2001-12-10 | 2007-11-22 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
| JP2005531574A (ja) * | 2002-05-22 | 2005-10-20 | アムジエン・インコーポレーテツド | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
| EP1578418A2 (en) * | 2002-12-20 | 2005-09-28 | Bayer HealthCare AG | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
| ES2337254T3 (es) | 2003-02-14 | 2010-04-22 | Glaxo Group Limited | Derivados de carboxamida. |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
-
2004
- 2004-08-05 FR FR0408652A patent/FR2874015B1/fr not_active Expired - Lifetime
-
2005
- 2005-02-08 UA UAA200702276A patent/UA90483C2/uk unknown
- 2005-08-02 SI SI200530600T patent/SI1776340T1/sl unknown
- 2005-08-02 AT AT05793766T patent/ATE416160T1/de active
- 2005-08-02 RS RSP-2009/0089A patent/RS50853B/sr unknown
- 2005-08-02 CA CA2576727A patent/CA2576727C/fr not_active Expired - Lifetime
- 2005-08-02 JP JP2007524371A patent/JP5100381B2/ja not_active Expired - Fee Related
- 2005-08-02 BR BRPI0513087-5A patent/BRPI0513087A/pt not_active Application Discontinuation
- 2005-08-02 ZA ZA200700999A patent/ZA200700999B/xx unknown
- 2005-08-02 AU AU2005279085A patent/AU2005279085B2/en not_active Ceased
- 2005-08-02 CN CN2005800296989A patent/CN101010297B/zh not_active Expired - Fee Related
- 2005-08-02 ME MEP-2009-366A patent/ME01663B/me unknown
- 2005-08-02 UY UY29046A patent/UY29046A1/es not_active Application Discontinuation
- 2005-08-02 EP EP05793766A patent/EP1776340B1/fr not_active Expired - Lifetime
- 2005-08-02 PL PL05793766T patent/PL1776340T3/pl unknown
- 2005-08-02 WO PCT/FR2005/002014 patent/WO2006024776A1/fr not_active Ceased
- 2005-08-02 ES ES05793766T patent/ES2318542T3/es not_active Expired - Lifetime
- 2005-08-02 PT PT05793766T patent/PT1776340E/pt unknown
- 2005-08-02 DE DE602005011450T patent/DE602005011450D1/de not_active Expired - Lifetime
- 2005-08-02 HR HR20090101T patent/HRP20090101T3/xx unknown
- 2005-08-02 EA EA200700400A patent/EA011714B1/ru not_active IP Right Cessation
- 2005-08-02 MX MX2007001436A patent/MX2007001436A/es active IP Right Grant
- 2005-08-02 NZ NZ552924A patent/NZ552924A/en not_active IP Right Cessation
- 2005-08-02 DK DK05793766T patent/DK1776340T3/da active
- 2005-08-02 KR KR1020077002714A patent/KR101215162B1/ko not_active Expired - Fee Related
- 2005-08-03 PE PE2005000900A patent/PE20060557A1/es not_active Application Discontinuation
- 2005-08-03 MY MYPI20053619A patent/MY139286A/en unknown
- 2005-08-04 AR ARP050103236A patent/AR050283A1/es not_active Application Discontinuation
- 2005-08-04 TW TW094126541A patent/TWI360538B/zh not_active IP Right Cessation
-
2007
- 2007-01-18 US US11/624,406 patent/US7384969B2/en not_active Expired - Fee Related
- 2007-01-23 IL IL180911A patent/IL180911A/en not_active IP Right Cessation
- 2007-01-29 EC EC2007007215A patent/ECSP077215A/es unknown
- 2007-02-01 CR CR8889A patent/CR8889A/es unknown
- 2007-02-05 TN TNP2007000041A patent/TNSN07041A1/fr unknown
- 2007-03-02 NO NO20071198A patent/NO340060B1/no not_active IP Right Cessation
- 2007-03-02 MA MA29730A patent/MA28845B1/fr unknown
-
2008
- 2008-04-25 US US12/109,388 patent/US7582671B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 CY CY20091100191T patent/CY1108816T1/el unknown
- 2009-07-21 US US12/506,322 patent/US7781477B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2402104T3 (es) | Uso de 2-aminoacetamidas sustituidas para el tratamiento o alivio de la ansiedad | |
| KR101736218B1 (ko) | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 | |
| CN102947265B (zh) | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 | |
| ME01663B (me) | Derivati N-(1H-indolil)-1H-indol-2-karboksamida, njihova priprema i njihova primena u terapiji | |
| DE60127595T2 (de) | Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen | |
| WO2010043721A1 (en) | Oxidase inhibitors and their use | |
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| EA201000609A1 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| EA005975B1 (ru) | Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора | |
| CN105873580B (zh) | 加巴喷丁类化合物与σ受体配体的组合物 | |
| KR20060010717A (ko) | 신규한 아릴피페라지닐 화합물 | |
| TW201836606A (zh) | 一種ｍｏｒ激動劑與ｋｏｒ激動劑聯合在製備緩解和／或治療疼痛的藥物中的用途 | |
| JP2006522041A (ja) | インドロンアセトアミド誘導体、その調製方法及びその使用 | |
| CN107922391B (zh) | 吡啶和嘧啶衍生物 | |
| CN107207449A (zh) | 用于治疗精神障碍的四唑衍生物 | |
| CN107531642B (zh) | 咪唑衍生物 | |
| JP2024514366A (ja) | 可溶性エポキシドヒドロラーゼ阻害剤としてのピペリジン尿素誘導体 | |
| ES2202348T3 (es) | Derivados del azabicicloheptano n-substituidos, como por ejemplo neurolepticos. | |
| HRP20100297T1 (hr) | Derivati n-(heteroaril)-1h-indol-2-karboksamida i njihova upotreba kao ligandi vaniloidnog receptora trpv1 | |
| CN108137566B (zh) | 三唑衍生物 | |
| CA2800836A1 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity | |
| CN104755461A (zh) | 作为trp通道拮抗剂的6-氨基吲哚衍生物 | |
| EA200702199A1 (ru) | Новые соединения для лечения воспалительных заболеваний | |
| WO2025252186A1 (zh) | 一种用作电压门控钠通道抑制剂的杂环类化合物及其药物组合物、药物制剂和应用 | |
| CN103121970B (zh) | 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用 |